ConductScience.org, home
A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus Infection
API referenceFor AI assistants

Trial · NCT05005507

Results by group12

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 12 of 12

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Percentage of Participants With Adverse Events (AEs)Arm 1: JNJ-73763989+Nucleos(t)Ide Analog (NA)+PegIFN-alpha-2a0Percentage of participants
Percentage of Participants With Serious Adverse Events (SAEs)Arm 1: JNJ-73763989+Nucleos(t)Ide Analog (NA)+PegIFN-alpha-2a0Percentage of participants
Percentage of Participants With Abnormalities in Clinical Laboratory TestsArm 1: JNJ-73763989+Nucleos(t)Ide Analog (NA)+PegIFN-alpha-2aHematology0Percentage of participants
Percentage of Participants With Abnormalities in Clinical Laboratory TestsArm 1: JNJ-73763989+Nucleos(t)Ide Analog (NA)+PegIFN-alpha-2aBlood coagulation0Percentage of participants
Percentage of Participants With Abnormalities in Clinical Laboratory TestsArm 1: JNJ-73763989+Nucleos(t)Ide Analog (NA)+PegIFN-alpha-2aBlood biochemistry0Percentage of participants
Percentage of Participants With Abnormalities in Clinical Laboratory TestsArm 1: JNJ-73763989+Nucleos(t)Ide Analog (NA)+PegIFN-alpha-2aUrinalysis0Percentage of participants
Percentage of Participants With Abnormalities in Clinical Laboratory TestsArm 1: JNJ-73763989+Nucleos(t)Ide Analog (NA)+PegIFN-alpha-2aUrine chemistry0Percentage of participants
Percentage of Participants With Abnormalities in Clinical Laboratory TestsArm 1: JNJ-73763989+Nucleos(t)Ide Analog (NA)+PegIFN-alpha-2aRenal biomarker0Percentage of participants
Percentage of Participants With Abnormalities in 12-Lead Electrocardiograms (ECGs)Arm 1: JNJ-73763989+Nucleos(t)Ide Analog (NA)+PegIFN-alpha-2a0Percentage of participants
Percentage of Participants With Abnormalities in Vital SignsArm 1: JNJ-73763989+Nucleos(t)Ide Analog (NA)+PegIFN-alpha-2a0Percentage of participants
Percentage of Participants With Virologic FlaresArm 1: JNJ-73763989+Nucleos(t)Ide Analog (NA)+PegIFN-alpha-2a0Percentage of participants
Percentage of Participants With Biochemical FlaresArm 1: JNJ-73763989+Nucleos(t)Ide Analog (NA)+PegIFN-alpha-2a0Percentage of participants

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT05005507/results

API referenceFor AI assistants